Top

Published in:

01-07-2018 | Original Article

Pasireotide treatment reduces cardiometabolic risk in Cushing’s disease patients: an Italian, multicenter study

Authors: A. Albani, F. Ferraù, A. Ciresi, R. Pivonello, C. Scaroni, D. Iacuaniello, M. Zilio, V. Guarnotta, A. Alibrandi, E. Messina, M. Boscaro, C. Giordano, A. Colao, S. Cannavo

Published in: Endocrine | Issue 1/2018

Abstract

Purpose

Patients with Cushing’s disease (CD) experience metabolic alterations leading to increased cardiovascular mortality. Recently, the visceral adiposity index (VAI) has been proposed as a marker of visceral adipose tissue dysfunction (ATD) and of the related cardiometabolic risk. We aimed to evaluate the impact of 12-month pasireotide treatment on cardiometabolic risk in CD patients.

Methods

This is a multicentre, prospective, and observational study. Sixteen CD patients, referred to the Endocrine Units of the University Hospitals of Messina, Napoli, Padova, and Palermo (Italy), successfully treated with pasireotide for 12 month have been enrolled. In all patients, we assessed anthropometric, clinical, and biochemical parameters and calculated VAI, ATD severity, Framingham, and atherosclerotic cardiovascular disease (ASCVD) risk scores, before and after 6 and 12 months of treatment with pasireotide (1200–1800 mcg/daily).

Results

Before starting pasireotide treatment, ATD was present in 7/16 patients (mild in 2/16, moderate in 3/16, and severe 2/16). After 12 months of treatment: (i) 24h-urinary free cortisol levels (p = 0.003), BMI (p < 0.001), waist circumference (p = 0.001), LDL-cholesterol (p = 0.033), total-cholesterol (p = 0.032), triglycerides (p = 0.030), VAI (p = 0.015), and ATD severity (p = 0.026) were significantly decreased as compared to baseline; (ii) ATD was present in only 1/16 patients; (iii) prevalence of diabetes mellitus (p = 0.015) and HbA1c levels (p = 0.001) were significantly increased as compared to baseline; (iv) Framingham and ASCVD risk scores were not significantly different from pre-treatment values.

Conclusions

Twelve-month pasireotide treatment significantly reduces VAI and ATD in CD patients. These positive effects on cardiometabolic risk occur despite no change in Framingham and ASCVD risk scores and the increase in the prevalence of diabetes mellitus.

R. Pivonello, M. De Leo, A. Cozzolino, A. Colao, The treatment of Cushing’s disease. Endocr. Rev. 36(4), 385–486 (2015). https://doi.org/10.1210/er.2013-1048 CrossRefPubMedPubMedCentral

R.N. Clayton, P.W. Jones, R.C. Reulen, P.M. Stewart, Z.K. Hassan-Smith, G. Ntali, N. Karavitaki, O.M. Dekkers, A.M. Pereira, M. Bolland, I. Holdaway, J. Lindholm, Mortality in patients with Cushing’s disease more than 10 years after remission: a multicentre, multinational, retrospective cohort study. Lancet Diabetes Endocrinol. 4(7), 569–576 (2016).https://doi.org/10.1016/S2213-8587(16)30005-5 CrossRefPubMed

O.M. Dekkers, N.R. Biermasz, A.M. Pereira, F. Roelfsema, M.O. van Aken, J.H. Voormolen, J.A. Romijn, Mortality in patients treated for Cushing’s disease is increased, compared with patients treated for nonfunctioning pituitary macroadenoma. J. Clin. Endocrinol. Metab. 92(3), 976–981 (2007). https://doi.org/10.1210/jc.2006-2112 CrossRefPubMed

G. Ntali, A. Asimakopoulou, T. Siamatras, J. Komninos, D. Vassiliadi, M. Tzanela, S. Tsagarakis, A.B. Grossman, J.A. Wass, N. Karavitaki, Mortality in Cushing’s syndrome: systematic analysis of a large series with prolonged follow-up. Eur. J. Endocrinol. 169(5), 715–723 (2013). https://doi.org/10.1530/EJE-13-0569 CrossRefPubMed

R. Pivonello, M.C. De Martino, M. De Leo, C. Simeoli, A. Colao, Cushing’s disease: the burden of illness. Endocrine (2016). https://doi.org/10.1007/s12020-016-0984-8

R. Pivonello, A.M. Isidori, M.C. De Martino, J. Newell-Price, B.M. Biller, A. Colao, Complications of Cushing’s syndrome: state of the art. Lancet Diabetes Endocrinol. 4(7), 611–629 (2016). https://doi.org/10.1016/S2213-8587(16)00086-3CrossRefPubMed

F. Ferrau, M. Korbonits, Metabolic comorbidities in Cushing’s syndrome. Eur. J. Endocrinol. 173(4), M133–M157 (2015). https://doi.org/10.1530/EJE-15-0354 CrossRefPubMed

D. Ferone, C. Pivonello, G. Vitale, M.C. Zatelli, A. Colao, R. Pivonello, Molecular basis of pharmacological therapy in Cushing’s disease. Endocrine 46(2), 181–198 (2014). https://doi.org/10.1007/s12020-013-0098-5 CrossRefPubMed

A. Colao, S. Petersenn, J. Newell-Price, J.W. Findling, F. Gu, M. Maldonado, U. Schoenherr, D. Mills, L.R. Salgado, B.M. Biller, B.S.G. Pasireotide, A 12-month phase 3 study of pasireotide in Cushing’s disease. N. Engl. J. Med 366(10), 914–924 (2012). https://doi.org/10.1056/NEJMoa1105743 CrossRefPubMed

10.

R. Pivonello, S. Petersenn, J. Newell-Price, J.W. Findling, F. Gu, M. Maldonado, A. Trovato, G. Hughes, L.R. Salgado, A. Lacroix, J. Schopohl, B.M. Biller, B.S.G. Pasireotide, Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing’s disease: results from a Phase III study. Clin. Endocrinol. 81(3), 408–417 (2014). https://doi.org/10.1111/cen.12431 CrossRef

11.

J. Schopohl, F. Gu, R. Rubens, L. Van Gaal, J. Bertherat, M. Ligueros-Saylan, A. Trovato, G. Hughes, L.R. Salgado, M. Boscaro, R. Pivonello, B.S.G. Pasireotide, Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing’s disease: results from an open-ended, open-label extension trial. Pituitary 18(5), 604–612 (2015). https://doi.org/10.1007/s11102-014-0618-1 CrossRefPubMed

12.

S. Petersenn, L.R. Salgado, J. Schopohl, L. Portocarrero-Ortiz, G. Arnaldi, A. Lacroix, C. Scaroni, S. Ravichandran, A. Kandra, B.M.K. Biller, Long-term treatment of Cushing’s disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial. Endocrine 57(1), 156–165 (2017). https://doi.org/10.1007/s12020-017-1316-3 CrossRefPubMedPubMedCentral

13.

R. Pivonello, G. Arnaldi, C. Scaroni, C. Giordano, S. Cannavò, D. Iacuaniello, L. Trementino, M. Zilio, V. Guarnotta, A. Albani, A. Cozzolino, G. Michetti, M. Boscaro, A. Colao, Pasireotide medical treatment in Cushing’s disease: an Italian multicenter experience based on “real world evidence”. Endocrine (2018)

14.

M.C. Amato, C. Giordano, Visceral adiposity index: an indicator of adipose tissue dysfunction. Int J. Endocrinol. 2014, 730827 (2014). https://doi.org/10.1155/2014/730827 CrossRefPubMedPubMedCentral

15.

M.C. Amato, C. Giordano, M. Galia, A. Criscimanna, S. Vitabile, M. Midiri, A. Galluzzo; AlkaMeSy Study, G., Visceral adiposity index: a reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care 33(4), 920–922 (2010). https://doi.org/10.2337/dc09-1825 CrossRefPubMedPubMedCentral

16.

A. Ciresi, M.C. Amato, V. Guarnotta, F. Lo Castro, C. Giordano, Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels. Clin. Endocrinol. 79(6), 845–852 (2013). https://doi.org/10.1111/cen.12204 CrossRef

17.

A. Ciresi, M.C. Amato, G. Pizzolanti, C. Giordano Galluzzo, Visceral adiposity index is associated with insulin sensitivity and adipocytokine levels in newly diagnosed acromegalic patients. J. Clin. Endocrinol. Metab. 97(8), 2907–2915 (2012). https://doi.org/10.1210/jc.2012-1518 CrossRefPubMed

18.

C. Giordano, V. Guarnotta, R. Pivonello, M.C. Amato, C. Simeoli, A. Ciresi, A. Cozzolino, A. Colao, Is diabetes in Cushing’s syndrome only a consequence of hypercortisolism? Eur. J. Endocrinol. 170(2), 311–319 (2014). https://doi.org/10.1530/EJE-13-0754 CrossRefPubMed

19.

D.C. Goff Jr., D.M. Lloyd-Jones, G. Bennett, S. Coady, R.B. D’Agostino Sr., R. Gibbons, P. Greenland, D.T. Lackland, D. Levy, C.J. O’Donnell, J.G. Robinson, J.S. Schwartz, S.T. Shero, S.C. Smith Jr., P. Sorlie, N.J. Stone, P.W. Wilson; American College of Cardiology/American Heart Association Task Force on Practice, G., 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 63(25 Pt B), 2935–2959 (2014). https://doi.org/10.1016/j.jacc.2013.11.005 CrossRefPubMed

20.

Standards of Medical Care in Diabetes-2016, Summary of revisions. Diabetes Care 39(Suppl 1), S4–S5 (2016). https://doi.org/10.2337/dc16-S003 CrossRef

21.

S.M. Grundy, H.B. Brewer Jr., J.I. Cleeman, S.C. Smith Jr., C. Lenfant; American Heart, A., National Heart, L., Blood, I., Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109(3), 433–438 (2004). https://doi.org/10.1161/01.CIR.0000111245.75752.C6 CrossRefPubMed

22.

M.C. Amato, C. Giordano, M. Pitrone, A. Galluzzo, Cut-off points of the visceral adiposity index (VAI) identifying a visceral adipose dysfunction associated with cardiometabolic risk in a Caucasian Sicilian population. Lipids Health Dis. 10, 183 (2011). https://doi.org/10.1186/1476-511X-10-183 CrossRefPubMedPubMedCentral

23.

A.M. Isidori, C. Graziadio, R.M. Paragliola, A. Cozzolino, A.G. Ambrogio, A. Colao, S.M. Corsello, R. Pivonello, A.B.C.S. Group, The hypertension of Cushing’s syndrome: controversies in the pathophysiology and focus on cardiovascular complications. J. Hypertens. 33(1), 44–60 (2015). https://doi.org/10.1097/HJH.0000000000000415 CrossRefPubMedPubMedCentral

24.

M.G. Baroni, F. Giorgino, V. Pezzino, C. Scaroni, A. Avogaro; Italian Society for Study of, D., Italian Endocrinological, S., Italian Society for the Study of Diabetes (SID)/Italian Endocrinological Society (SIE) guidelines on the treatment of hyperglycemia in Cushing’s syndrome and acromegaly. Nutr. Metab. Cardiovasc Dis. 26(2), 85–102 (2016). https://doi.org/10.1016/j.numecd.2016.02.001 CrossRefPubMed

25.

A. Colao, C. De Block, M.S. Gaztambide, S. Kumar, J. Seufert, F.F. Casanueva, Managing hyperglycemia in patients with Cushing’s disease treated with pasireotide: medical expert recommendations. Pituitary 17(2), 180–186 (2014). https://doi.org/10.1007/s11102-013-0483-3 CrossRefPubMed

26.

M.C. Amato, G. Pizzolanti, V. Torregrossa, G. Misiano, S. Milano, C. Giordano, Visceral adiposity index (VAI) is predictive of an altered adipokine profile in patients with type 2 diabetes. PLoS One 9(3), e91969 (2014). https://doi.org/10.1371/journal.pone.0091969 CrossRefPubMedPubMedCentral

27.

M.C. Amato, M. Verghi, A. Galluzzo, C. Giordano, The oligomenorrhoic phenotypes of polycystic ovary syndrome are characterized by a high visceral adiposity index: a likely condition of cardiometabolic risk. Hum. Reprod. 26(6), 1486–1494 (2011). https://doi.org/10.1093/humrep/der088 CrossRefPubMed

28.

I.I. Androulakis, E. Kandaraki, C. Christakou, A. Karachalios, E. Marinakis, T. Paterakis, E. Diamanti-Kandarakis, Visceral adiposity index (VAI) is related to the severity of anovulation and other clinical features in women with polycystic ovary syndrome. Clin. Endocrinol. 81(3), 426–431 (2014). https://doi.org/10.1111/cen.12447 CrossRef

29.

A. Ciresi, S. Radellini, V. Guarnotta, C. Giordano, The visceral adiposity index is associated with insulin sensitivity and IGF-I levels in adults with growth hormone deficiency. Endocrine 56(3), 579–588 (2017). https://doi.org/10.1007/s12020-016-1076-5 CrossRefPubMed

30.

C. Di Somma, A. Ciresi, M.C. Amato, S. Savastano, M.C. Savanelli, E. Scarano, A. Colao, C. Giordano, Alteration of the growth hormone axis, visceral fat dysfunction, and early cardiometabolic risk in adults: the role of the visceral adiposity index. Endocrine 49(2), 492–502 (2015). https://doi.org/10.1007/s12020-014-0471-z CrossRefPubMed

31.

A. Giandalia, G.T. Russo, E.L. Romeo, A. Alibrandi, P. Villari, A.A. Mirto, G. Armentano, S. Benvenga, D. Cucinotta, Influence of high-normal serum TSH levels on major cardiovascular risk factors and Visceral Adiposity Index in euthyroid type 2 diabetic subjects. Endocrine 47(1), 152–160 (2014). https://doi.org/10.1007/s12020-013-0137-2 CrossRefPubMed

32.

R.S. Auriemma, L. Granieri, M. Galdiero, C. Simeoli, Y. Perone, P. Vitale, C. Pivonello, M. Negri, T. Mannarino, C. Giordano, M. Gasperi, A. Colao, R. Pivonello, Effect of cabergoline on metabolism in prolactinomas. Neuroendocrinology 98(4), 299–310 (2013). https://doi.org/10.1159/000357810 CrossRefPubMed

33.

F. Ferrau, F. Spagnolo, O.R. Cotta, L. Cannavo, A. Alibrandi, G.T. Russo, T. Aversa, F. Trimarchi, S. Cannavo, Visceral adiposity index as an indicator of cardiometabolic risk in patients treated for craniopharyngioma. Endocrine (2016). https://doi.org/10.1007/s12020-016-1196-y

Title: Pasireotide treatment reduces cardiometabolic risk in Cushing’s disease patients: an Italian, multicenter study
Authors: A. Albani
F. Ferraù
A. Ciresi
R. Pivonello
C. Scaroni
D. Iacuaniello
M. Zilio
V. Guarnotta
A. Alibrandi
E. Messina
M. Boscaro
C. Giordano
A. Colao
S. Cannavo
Publication date: 01-07-2018
Publisher: Springer US
Published in: Endocrine / Issue 1/2018
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-018-1524-5

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Pasireotide treatment reduces cardiometabolic risk in Cushing’s disease patients: an Italian, multicenter study

Abstract

Purpose

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2018

Screening for comorbid conditions in patients enrolled in the SODA registry: a 2-year observational analysis

Standardization of simple auxiliary method beneficial to total endoscopic thyroidectomy on patients with PTC, based on retrospective study of 356 cases

Hyperirisinemia is independently associated with subclinical hypothyroidism: correlations with cardiometabolic biomarkers and risk factors

Predictivity of clinical, laboratory and imaging findings in diagnostic definition of palpable thyroid nodules. A multicenter prospective study

Practical issues for the management of hyponatremia in oncology

Thyroid cancer-related bone metastases: increasingly good prospects for treatment

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page